186 related articles for article (PubMed ID: 9573106)
1. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.
Wessels MR; Paoletti LC; Guttormsen HK; Michon F; D'Ambra AJ; Kasper DL
Infect Immun; 1998 May; 66(5):2186-92. PubMed ID: 9573106
[TBL] [Abstract][Full Text] [Related]
2. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
[TBL] [Abstract][Full Text] [Related]
3. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
Madoff LC; Paoletti LC; Tai JY; Kasper DL
J Clin Invest; 1994 Jul; 94(1):286-92. PubMed ID: 7518832
[TBL] [Abstract][Full Text] [Related]
4. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
[TBL] [Abstract][Full Text] [Related]
5. Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine.
Marques MB; Kasper DL; Shroff A; Michon F; Jennings HJ; Wessels MR
Infect Immun; 1994 May; 62(5):1593-9. PubMed ID: 8168919
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Rodewald AK; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1993 Nov; 61(11):4760-6. PubMed ID: 8406875
[TBL] [Abstract][Full Text] [Related]
7. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; LagergÄrd T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
8. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
[TBL] [Abstract][Full Text] [Related]
11. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus.
Paoletti LC; Kasper DL; Michon F; DiFabio J; Holme K; Jennings HJ; Wessels MR
J Biol Chem; 1990 Oct; 265(30):18278-83. PubMed ID: 2120228
[TBL] [Abstract][Full Text] [Related]
12. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
Paoletti LC; Kasper DL; Michon F; DiFabio J; Jennings HJ; Tosteson TD; Wessels MR
J Clin Invest; 1992 Jan; 89(1):203-9. PubMed ID: 1729272
[TBL] [Abstract][Full Text] [Related]
13. Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.
Michon F; Uitz C; Sarkar A; D'Ambra AJ; Laude-Sharp M; Moore S; Fusco PC
Clin Vaccine Immunol; 2006 Aug; 13(8):936-43. PubMed ID: 16893995
[TBL] [Abstract][Full Text] [Related]
14. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.
Shen X; LagergÄrd T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Infect Immun; 2001 Jan; 69(1):297-306. PubMed ID: 11119518
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Pinel J; Kasper DL
J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons.
Paoletti LC; Kennedy RC; Chanh TC; Kasper DL
Infect Immun; 1996 Feb; 64(2):677-9. PubMed ID: 8550227
[TBL] [Abstract][Full Text] [Related]
17. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1992 Oct; 60(10):4009-14. PubMed ID: 1398913
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.
Gudlavalleti SK; Lee CH; Norris SE; Paul-Satyaseela M; Vann WF; Frasch CE
Vaccine; 2007 Nov; 25(46):7972-80. PubMed ID: 17936445
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid.
Lagergard T; Shiloach J; Robbins JB; Schneerson R
Infect Immun; 1990 Mar; 58(3):687-94. PubMed ID: 2407652
[TBL] [Abstract][Full Text] [Related]
20. Conjugate vaccines against group B Streptococcus types IV and VII.
Paoletti LC; Kasper DL
J Infect Dis; 2002 Jul; 186(1):123-6. PubMed ID: 12089673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]